_10_ŁlŒ¼,‚¼
|
|
|
- つねとき ごちょう
- 7 years ago
- Views:
Transcription
1 ) * 1) 1) 1) 1) 1) 1) 1) 1) 1) 1) Jia Yu 1) 1) 1) 1) 1) HPLC ) *
2 90 DNA DNA 1) S 50S trna 30S trna 50S trna II DNAgyrase DNA DNA 2-6) 7) 4) Gammaproteobacteria Enterobacteriales Escherichia coli Gammaproteobacteria Pseudomonadales Pseudomonas aeruginosa Bacilli Bacillales Bacillus subtilis Bacilli Lactobacillales Enterococcus faecalis 50 HPLC 4) - G
3 91 quinoline Alanine racemase -alanine- -alanine ligase - -cycloserine Sigma USA Escherichia coli IAM Pseudomonas aeruginosa IAM 1514 Bacillus subtilis IAM Enterococcus faecalis JCM 5803 Type strain IAM Culture Collection Japan Collection of Microorganisms JCM E. coli GN 4351 P. aeruginosa GN231 Nutrient Broth NB Trypticase Soy Broth TSB Becton Dickinson USA Brain Heart Infusion Broth BHIB GAM RPMI Eagle MEM MEM Fisher s FM SM+ -Ala -alanine -alanine SM+ -Ala 37 NB TSB BHIB GAM MEM FM SM 199 -Ala 4ml 10 l nm minimum growthinhibitory concentration MIC 50% 50% fifty percent growthinhibitory concentration IC 50 g/ml 100% IC 50 10,000 xg 10 M150 IC 50 PBS 10% 1.0M HClO 4 PCA 200 l PCA 5-7% DISMIC-13HP 100 l L6000 o- OPA - HPLC 8) 100 l HPLC 2619F 4mm x 50mm 70 NaCl- / OPA 70 1,3-diaminopropane Dap putrescine Put cadaverine Cad spermidine Spd spermine Spm agmatine Agm N 1 - N 1 -acetylspermidine AcSpd Sigma USA aminopropylcadaverine APCad ) - N 1 - -
4 ) NB GAM mol/g wet weight Table 1 TSB BHIB NB GAM MIC 50% IC 50 HPLC VCM D-CS -alanine - -alanine SM 199 NB GAM VCM D-CS NB 199 GAM - -alanine SM+ -Ala SM+ -Ala HPLC Fig 1-1A SM 199 NB Fig 3-2 A-control Fig 4-2 A-control Fig 5-2 A1-control 1 Cellular concentration of polyamines of Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Enterococcus faecalis, and polyamine content of Nutrient Broth and liquid GAM medium used for their culture. Typical data from Fig. 1-1 (E. faecalis grown in GAM), Fig. 3-2 (P. aeruginosa grown in NB) and Fig. 5-2 (E. coli grown in NB, B. subtilis grown in NB, E. faecalis grown in NB) are shown. Bacteria growing at 37 were harvested at late-exponentially growing phase. T, Type strain. Abbreviations for polyamines are as shown in Fig. 1-1.
5 93 Fig 1-1B NB HPLC Fig 4-2 B-control Fig 5-2 B-control NB GAM GAM Fig 1-1C NB Fig 4-2 C-control Fig 5-2 C-control SM+ -Ala SM+ -Ala D-CS Fig 1-2 A B C 1 1 HPLC analysis of polyamines extracted from Escherichia coli IAM (A), Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) grown in the complete synthetic medium supplemented with -alanine (SM+ -Ala), synthetic 199 medium (199) and GAM medium (GAM) in the absence (control) or presence of Vancomycin (VCM) at the concentration (IC50), shown as arrow in Fig Bacteria growing at 37 were harvested at late-exponentially growing phase. Abbreviations for polyamines: Dap, diaminopropane; Put, putrescine; Cad, cadaverine; Spd, spermidine; APCad, aminopropylcadaverine ; Spm, spermine; Agm, agmatine; AcSpd, N 1 -acetylspermidine. Printed numbers on elution peaks are corresponded to the elution time in scale of abscissa (min). Relative fluorescence and elution times are omitted in other HPLC chromatograms in the present study.
6 94 D-alanine MIC 50 IC50 D-alanine D- CS D-CS Alanine racemase D-Alanine-D-alanine ligase SM+ -Ala SM+D-Ala D-CS VCM NB 80 g/ml VCM 199 GAM VCM Fig 1-2D 2E 50 D E control HPLC Fig 1-1B 1C VCM - VCM VCM 1 2 Growth inhibition curves of Escherichia coli IAM 12119, Bacillus subtilis IAM and Enterococcus faecalis JCM 5803 in the complete synthetic medium containing -Ala (SM+ -Ala) ( ) or -Ala (SM+ - Ala) ( ) (in Figs. A-C), synthetic 199 medium (in Fig. D) ( ) or GAM medium (in Fig. E) ( )by -Cycloserine ( - CS) or Vancomycin (VCM). The growth of Escherichia coli was not inhibited by VCM at the concentration of 80 g/ml. Arrow indicates the fifty percent growthinhibitiory concentration (IC50) by VCM (Figs. D and E).
7 95 NB PCG PIPC FMOX 50 IC 50 Fig IC 50 PCG 18 g/ml PIPC 0.5 g/ml FMOX 0.09 g/ml PCG 8 g/ml PIPC 12 g/ml FMOX 0.08 g/ml PCG 0.7 g/ml PIPC 0.4 g/ml FMOX 36 g/ml PCG PIPC FMOX IC 50 HPLC Fig 2-1 A 600nm pmol Fig % PIPC FMOX Fig 2-2A PIPC 1 g/ml Fig 2-1A Fig 2-2B PIPC - PIPC NB NB Table1 PCG PIPC FMOX Fig 2-2C FMOX PCG PIPC Growth inhibition curves of Escherichia coli IAM (A), Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) in Nutrient Broth by Benzylpenicillin (Penicillin G)(PCG), Piperacillin (PIPC) or Flomoxef (FMOX). Arrows indicate the tubes near at IC50 used for polyamine analysis.
8 Cellular polyamine content (pmol /absorbance at 600 nm for growth turbidity) of Escherichia coli IAM (A), Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) grown in Nutrient Broth in the presence of Benzylpenicillin (Penicillin G) (PCG), Piperacillin (PIPC) or Flomoxef (FMOX) at the concentrations shown as arrows in Fig Abbreviations for polyamines are as shown in Fig KM Aminoglycoside acetyltransferase ACC 6 GN231 SM Aminoglycoside adenyltransferase AAD 3 GN ,15) KM SM Fig 3-1 NB SM 30 KM KM SM 50 HPLC KM OPA 16) HPLC KM Fig 3-2C D SM SM KM HPLC Fig 3-2 IC g/ml Fig 3-2A SM Fig 3-2B SM g/ml Fig 3-2B KM KM Fig 3-2C KM
9 97 HPLC Fig 3-3 Gammaproteobacteria Pseudomonas KM 6 -NH 2 KM N 1 - NB EM TC CP Fig IC 50 Fig 4-1A 1B 1C TC Fig 4-2 CP EM NB SM+L-Ala Fig 4-3 SM 200 g/ml 1mM EM Fig 4-3 EM KM SM NB 1mM Fig 4-2D 2E Fig 4-2A control Fig 4-2D control NB EM 50% Fig 4-2D 2E SM 3 1 Growth inhibition curves of Escherichia coli IAM (sensitive Type strain) and E. coli GN3451(SM-resistant strain) grown in Nutrient Broth by Streptomycin (SM) (A), and Pseudomonas aeruginosa IAM 1514 (sensitive Type strain) and P. aeruginosa GN231 (KM-resistant strain) grown in Nutrient Broth by Kanamycin (KM) (B). Arrows indicate about IC50 in this experiment.
10 HPLC analysis of polyamines extracted from the cells of Escherichia coli IAM (sensitive Type strain) (A) and E. coli GN3451 (SM-resistant strain) (B), and the culture supernatant (Sup) grown in Nutrient Broth in the absence (control) or presence of Streptomycin (SM) at the concentration of IC50, and the cells of Pseudomonas aeruginosa IAM 1514 (sensitive Type strain) (C) and P. aeruginosa GN231 (KM-resistant strain) (D), and the culture supernatant (Sup), grown in Nutrient Broth in the absence (control) or presence of Kanamycin (KM) at the concentration of 100 or 200 g/ml. Abbreviations for polyamines are as shown in Fig. 1-1.
11 Comparisons of polyamine distributions in the cells of Escherichia coli IAM (sensitive Type strain) (A), E. coli GN3451 (SM-resistant strain) (B), Pseudomonas aeruginosa IAM 1514 (sensitive Type strain) (C) and P. aeruginosa GN231 (KM-resistant strain) (D). The bacteria were grown in Nutrient Broth in the absence (control) or presence of Streptomycin (SM) or Kanamycin (KM) at the concentration of IC50. Polyamine contents ( mol/wet weight of cells) were shown as a percent (%) against to the total of cellular polyamines ( mol/wet weight of cells). Abbreviations for polyamines are as shown in Fig Fig 5-1 SM+L-Ala NB OFLX 4 1 Growth inhibition curves of Escherichia coli IAM (A), Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) in Nutrient Broth in the presence of Erythromycin (EM), Chloramphenicol (CP) or Tetracyclin (TC). c, control (0 g/ml). Arrows indicate the tubes near at IC50. NFLX OFLX Fig 5-2 OFLX 50 IC 50 NB Fig.5-1 HPLC SM OFLX NB
12 HPLC analysis of polyamines extracted from Escherichia coli IAM (A), Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) grown in Nutrient Broth in the absence (control) or presence of Erythromycin (EM), Chloramphenicol (CP) or Tetracycline (TC) at the concentrations shown as arrow in Fig HPLC analysis of polyamines extracted from Escherichia coli IAM grown in Nutrient Broth (NB) containing 200 g/ml of spermidine (D) or the complete synthetic medium (SM+ -Ala) containing 200 g/ml of spermidine (E), in the absence (control) or presence of Erythromycin at the concentration (IC50) as shown in Fig Abbreviations for polyamines are as shown in Fig. 1-1.
13 Growth inhibition curves of Escherichia coli IAM in Nutrient Broth (NB) or the complete synthetic medium (SM+ - Ala) (SM) by Erythromycin in the absence or presence of spermidine (Spd) at the concentration of 200 g/ml. c, control (0 g/ml). Arrows indicate the tube near at IC Growth inhibition curves of Escherichia coli IAM 12119, Bacillus subtilis IAM and Enterococcus faecalis JCM 5803 in Nutrient Broth (NB) or the complete synthetic medium (SM+L-Ala) by Ofloxacin (OFLX). c, control (0 g/ml). The cells in the tube of the arrow were subjected to polyamine analysis. 5 2 HPLC analysis of polyamines extracted from Escherichia coli IAM (A) Bacillus subtilis IAM (B) and Enterococcus faecalis JCM 5803 (C) grown in Nutrient Broth (NB) (A-1, B, C) or the complete synthetic medium (SM+ -Ala) (A-2) in the absence (control) or presence of Ofloxacin (OFLX) at the concentrations shown as arrows in Fig Abbreviations for polyamines are as shown in Fig. 1-
14 102 Fig 5-2 A-1 A-2 NB OFLX NB OFLX SM 199 NB GAM Fig 6-1 TSB BHIB NB Fig 3-2 Fig 4-2 RPMI1640 FM 199 Fig Fig.6-1A SM Fig.1-3 Fig 5-2 Fig 6-1B NB Fig 6-1C Fig 6-1D SM 199 SM Fig 6-1E 1mM 199 1mM Fig 6-1E RNA RNA rrna RNA trna RNA mrna 5,18-20) RNA DNA 21) 50
15 6 1 HPLC analysis of polyamines extracted from the cells of Escherichia coli IAM grown in Tripticase Soy Broth (TSB), Brain Heart Infusion Broth (BHIB), RPMI1640 medium (1640) and Fisher s medium (FM) (A), and the culture supernatant (Sup) after the cultivation in the media (B). Polyamines extracted from the cells of Pseudomonas aeruginosa IAM 1514 grown in 199 medium or 1640 medium(c). Polyamines extracted from the cells of Bacillus subtilis IAM grown in 1640 medium and its Sup (D). Polyamines extracted from the cells of Enterococcus faecalis JCM 5803 grown in 199 medium, 1640 medium, the 199 medium supplemented with 1 mm spermidine (Spd) or the 1640 medium supplemented with 1 mm spermidine (Spd) (E). Abbreviations for polyamines are as shown in Fig
16 104 Polyamine World in Life ) ) ) Cohen SS. A guide to the polyamines. Oxford University Press, Oxford, Hamana K, Satake S. Absence of cellular polyamines in gram-positive anaerobic cocci and lactic acid bacteria. J Gen Appl Microbiol Hamana K, Akiba T, Uchino F, Matsuzaki S. Distribution of spermine in bacilli and lactic acid bacteria. Can J Microbiol Hamana K. Distribution of diaminopropane and acetylspermidine in Enterobacteriaceae. Can J Microbiol Hamana K. Polyamine distribution catalogues of clostridia, acetogenic anaerobes, actinobacteria, bacilli, heliobacteria and haloanaerobes within gram-positive eubacteria. Microbiol Cult Coll Hamana K, Sakamoto A, Tachiyanagi S, Terauchi E. Polyamine profiles of some members of the gamma subclass of the class Proteobacteria Polyamine analysis of twelve recently described genera. Microbiol Cult Coll : Hamana K, Satake S, Iyobe S, Matsuzaki S. Polyamine distribution patterns in Pseudomonas, Alkaligenes and Comamonas. Ann Rep Coll Med Care Technol Gunma Univ ) HPLC Kouvel EC, Petropoulos AD, Kalpaxis DL. Unraveling new features of clindamycin interaction with functional ribosomes and dependence of the drug potency on polyamines. J Biol Chem Kwon DH, Lu CD. Polyamine effects on antibiotic susceptibility in bacteria. Antimicrob Agents Chemother
17 105 Escherichia coli, Pseudomonas aeruginosa Bacillus subtilis Enterococcus faecalis Koei HAMANA 1) *, Yoko YOKOYAMA 1), Satomi TACHIYANAGI 1), Rie TERAUCHI 1), Tomomi AIZAKI 1), Eri ARAI 1), Aya SAITO 1), Kaoru UCHIKATA 1), Hajime OHNISHI 1), Wakako SATO 1), Kanako GOUMA 1), Jia Yu 1), Yurie INO 1), Yukiko UMEMURA 1), Chiharu MOCHIDUKI 1) and Ryuichi HOSOYA 1) Cellular polyamines extracted from the bacteria Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Enterococcus faecalis grown in the absence or presence of antibiotics belonging to seven chemical families, at fifty percent growth- inhibitory concentration (IC50 ), were analyzed by high performance liquid chromatography (HPLC). E. coli synthesize putrescine (Put), cadaverine(cad), agmatine(agm), spermidine(spd) and acetylspermidine(acspd), P. aeruginosa Put, Cad and Spd, and B. subtilis Put, Spd and Agm. E. faecalis produce no polyamines and uptake Spd from media. Cellular levels of the polyamines were compared between control bacteria and the inhibited bacteria by antibiotics. All polyamine levels in E. coli, and Spd and/or Agm levels in B. subtilis and E. faecalis were not sensitive for the presence of Vancomycin (glycopeptide). By Benzylpenicillin, Piperacillin and Flomoxef ( -luctam), Put, Cad, AcSpd were decreased and Spd was increased in E. coli, and Spd in B. subtilis and E. faecalis was decreased. Streptomycin, Kanamycin and Amikacin (aminoglycoside) repressed acetylation of Spd in E. coli and Cad synthesis in P. aeruginosa, including sensitive and resistant strains for the drugs. AcSpd level in E. coli and Spd level in B. subtilis and E. faecalis were decreased in the presence of Erythromycin (macrolide), Tetracycline (tetracycline) and Chloramphenicol (phenylalanine derivative). AcSpd, Put and Cad in E.coli and Spd in B. subtilis were decreased whereas Spd was not effective to Ofloxacin and Norfloxacin (pyridone carboxylic acid). AcSpd synthesis in E. coli was inhibited whereas Spd uptake in E. faecalis was not, by the antibiotics. Antibiotics, Bacillus subtilis, Enterococcus faecalis, Escherichia coli, Polyamine 1) School of Health Sciences, Faculty of Medicine, Gunma University Maebashi, Gunma , Japan * Reprint address
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
VOL. 36 S-3 CHEMOTHERAPY 437
VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,
dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na
Key words: Shigella, Bacterial resistance against entibiotics. Distribution of R factors dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc),
Takio ICHITANI and Teruko HIGASHIKAWA: Germination of Aphanomyces iridis oospores on the basal medium for selective isolation with addition of bacteri
Takio ICHITANI and Teruko HIGASHIKAWA: Germination of Aphanomyces iridis oospores on the basal medium for selective isolation with addition of bactericides and fungicides Summary This study examined the
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
Cephaloridine Conc. 125mcg/m/+ DC 10mg/ml Cephaloridine Conc. 125mcg/ml C- adap+ E. coli Ampicillin Conc. 125mcg/ml+C 10mg/ml Cephaloridine Conc. 12.5mcg/ml D-adap+E.coil JORGENSEN : Alteration of bile
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali
CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli
Key words: Pseudomonas aeruginosa, fosfomycin, ofloxacin, Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacillin,
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1
Levloxacin V.:1 Z iiiir fa L CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d. 0.39 Đg/ml, 2h; e b b. 0.10 Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1992 0.39 Đg/ml, and Fig.
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
Effects of Light and Soil Moisture Condition on the Growth of Seedlings for Quercus serrata and Quercus variabilis NISHIMURA, Naoyuki*, OTA, Takeshi**
Effects of Light and Soil Moisture Condition on the Growth of Seedlings for Quercus serrata and Quercus variabilis NISHIMURA, Naoyuki*, OTA, Takeshi**, SAKAMOTO, Keiji*** and CHIBA, Kyozo*** Key words:
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
15) Egawa, R., Sawai, T. and Mit.uhashi, S.: Jap. J. Microbiol., 11 : 173-178, 1967. 16) Tanaka, T. and Hashimoto, H., Nagai, Y. and Mitsuhashi, S.: Jap. J. Microbiol., 11: 155-162, 1967. 17) Mitsuhashi,
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
"G um exp." in the table means before the gum chewing experiment, and "Cont exp." in the table means Table 1. Rest values of heart rate (HR), coefficient of variation in RR (CVRR), wave height of plethysmogram
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
CHEMOTHERAPY MAY 1988 Table 1 Media used for preculture and MIC determination *BHIB: Brain heart infusion broth (Difco), B-NAD: B-Nicotinamide adenine dinucleotide (Sigma chemical Co.), GAMB GAM broth
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
JUNE 1988
JUNE 1988 VOL.36 S-2 CHEMOTHERAPY Table 1. Antibacterial activity of NY-198 against standard strains of bacteria By the agar-dilution method (inoculum: 106 CFU/ml) JUNE 1988 Fig. 3. Antibacterial activity
Pseudomonas aeruginosa S-827 Fig. 1. Method of biofilm formation. Table 1. Susceptibilities of antimicrobial agents on agar plate and in broth against Pseudomonas aeruginosa S-827 JULY CHEMOTHERAPY 888
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
報告書 H22-2A-09
061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
総 説 6 6 PIMs P S J 7
2018 10 1-6 総 説 2018 P S J 1 2018 10 7-13 総 説 6 6 PIMs P S J 7 2018 10 19-29 誌上シンポジウム JASDS DSM 1997 2012 15 DSM DSSP JASDS DSM DSSP P S J 19 2018 10 30-34 誌上シンポジウム ADME 30 Pharmacy Society of Japan 2018
03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates
Effect of Cooking Water ph on Commercial Sterility in the Production of Cooked Rice Packed under Semi-aseptic Condition Kinya SAKUMAl, Haruhiko KATODA1, Tetsuya FUKAYA2, Toshio JOH3, Akira IT03 and Atsuo
Study on Application of the cos a Method to Neutron Stress Measurement Toshihiko SASAKI*3 and Yukio HIROSE Department of Materials Science and Enginee
Study on Application of the cos a Method to Neutron Stress Measurement Toshihiko SASAKI*3 and Yukio HIROSE Department of Materials Science and Engineering, Kanazawa University, Kakuma-machi, Kanazawa-shi,
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
CHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin Table 1 Differentiation of group D streptococcia aderived from R.R.Facklam1,2),K.C.Gross-et al3),and
Key words: Streptococcus agalactiae, Group B Streptococci, Chloramphenicol resistance Chloramphenicol acetyltransferase
Key words: Streptococcus agalactiae, Group B Streptococci, Chloramphenicol resistance Chloramphenicol acetyltransferase Table 1 Properties of Bacterial strains used CP: Chloramphenicol TC: Tetracycline
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
Studies on the nutritional physiology of rice stem rot fungi, Leptosphaeria salvinii and Helminthosporium sigmoideum var. irregulare (II) On the carbo
九州大学学術情報リポジトリ Kyushu University Institutional Repository 稲小粒菌核病菌の栄養生理に関する研究 ( 第 2 報 ) : 炭素源及び窒素源について 野中, 福次九州大学農学部植物病理学教室 Nonaka, Fukuji Laboratory of Plant Pathology, Faculty of Agriculture, Kyushu University